U.S. FDA-registered 503B outsourcing facility,
Wells Pharma of Houston, will compound and distribute Niagen
(nicotinamide riboside chloride) IV and injections to Cenegenics,
Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing,
The NAD MD, Next Health, The Remedy Room, Restore Hyper Wellness,
and REVIV
ChromaDex Corp. (NASDAQ:CDXC), the global authority on
nicotinamide adenine dinucleotide (NAD+) research with a focus on
healthy aging, announces Wells Pharma of Houston will begin
shipping limited quantities of pharmaceutical-grade Niagen®
(patented nicotinamide riboside chloride or NRC), branded Niagen+,
to select IV clinics including Cenegenics, Clean Market/NutriDrip,
Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next
Health, The Remedy Room, Restore Hyper Wellness, and REVIV in
August, with additional clinics set to receive shipments soon
after. U.S. FDA-registered 503B outsourcing facility, Wells Pharma
of Houston, will compound and distribute pharmaceutical-grade
intravenous (IV) and injectable Niagen, which will be available in
IV, shots, and intravenous-push forms exclusively at clinics, with
a prescription.
“Science-based health clinics nationwide are eager to offer
Niagen IV as a superior alternative to NAD+ IV,” said Rob Fried,
CEO of ChromaDex. “We welcome this group of clinics as the first to
offer Niagen IV and look forward to announcing additional
availability soon.”
Niagen IV represents a significant advancement in intravenous
NAD+ therapy. Compared to standard NAD+ IV treatments, Niagen IV
offers superior tolerability, a 75% shorter infusion time, and a
higher, faster rise in NAD+ blood levels three hours post-infusion,
as measured by NAD+ dried blood spot tests (MedRxiv).
Increasing interest in intravenous therapies positions Niagen+
for significant growth within the intravenous hydration therapy
market, valued at over $2.32 billion globally and $1.15 billion in
North America in 2022 (Grand View Research). With an order already
placed by Wells Pharma of Houston securing pharmaceutical-grade
Niagen for clinics beyond August and hundreds more clinics in the
pipeline for the rest of the year, Niagen IV is well-situated to
cover the entirety of the US intravenous hydration market with
ChromaDex’s new, superior product. Additionally, with the
popularity of IV and injection procedures on the rise, we see
significant opportunity to further expand into categories such as
medical spas, with 11,000 locations operating in the US alone,
according to the American Med Spa Association.
Kris Fishman, President of Wells Pharmacy Network, said, “We are
thrilled to collaborate with ChromaDex on Niagen+. Through our 503B
pharmacy network, we will compound this innovative product for
clinics across the U.S.”
Clean Market/NutriDrip, Next Health, REVIV, and Restore Hyper
Wellness celebrate the launch of Niagen+:
- Asa Kitfield, Managing Partner at Clean Market & NutriDrip,
remarked, “We are thrilled to unveil Niagen IV at Clean Market
locations and The Spa by Equinox Hotels at Hudson Yards as a
groundbreaking wellness solution that perfectly aligns with our
commitment to enhancing health and vitality. Niagen IV offers
reduced side effects and a shorter infusion time, making it more
compelling than traditional NAD+ infusions. This means our clients
can enjoy the benefits of enhanced cellular health and energy
production with greater comfort and ease. We are confident
pharmaceutical grade Niagen will become a cornerstone of our
injectable wellness treatments, delivering the exceptional results
our clients expect.”
- Darshan Shah, M.D., board-certified surgeon, founder of Next
Health, and ChromaDex consultant, noted, “Niagen IV is a game
changer, minimizing the unpleasant side effects of NAD+ IV and
maximizing absorption. The approach ChromaDex has taken with their
hero ingredient, nicotinamide riboside chloride (NRC), finally
makes IV therapy for mitochondrial health a true reality."
- Johnny Parvani, M.D., Founder and Chief Medical Officer of
REVIV, added, “I am thrilled to launch Niagen IV and injections to
our network of healthcare practitioners. Validated by extensive
research, this groundbreaking product features ChromaDex's
proprietary nicotinamide riboside chloride (NRC) technology to
support cellular health. At REVIV, we are committed to pioneering
solutions that enhance human health for our customers. As a better
alternative to NAD+ IV, we believe Niagen IV and injections will
redefine the longevity wellness category, enabling healthcare
providers to optimize patient outcomes with an innovation backed by
the highest scientific and quality standards.”
- Rachele Pojednic, PhD, Director of Scientific Research at
Restore Hyper Wellness, commented, "After completing an extensive
study on Niagen IV, in partnership with ChromaDex, we are impressed
by its significant potential to promote longevity and enhance
overall health.”
Clinics and healthcare providers interested in offering Niagen
IV and injections to patients can email ChromaDex’s Vice President
of Business Development, Eric Huynh, at support@niagenplus.com.
Consumers can visit www.niagenplus.com to sign up for product news
and updates on future clinic availability and use the store locator
to find a clinic offering Niagen IV and injections near you.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to rolling out limited
quantities of pharmaceutical-grade Niagen (patented nicotinamide
riboside chloride or NRC), branded Niagen+, to select IV clinics
including Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN
IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room,
Restore Hyper Wellness, and REVIV in August, with additional
clinics set to receive shipments soon. Statements that are not a
description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects," "anticipates," "intends," "estimates,"
"plans," "potential," "possible," "probable," "believes," "seeks,"
"may," "will," "should," "could" or the negative of such terms or
other similar expressions, and include the statements regarding
Niagen IV being available starting in August and nationwide
thereafter; Niagen IV’s potential to reach the global intravenous
hydration therapy and spa markets; the potential health benefits of
Niagen IV; and the potential for Niagen IV to materially impact the
overall NAD+ industry. These forward-looking statements are based
on the Company’s current expectations and are subject to risks and
uncertainties that may cause actual results to differ materially,
including unanticipated developments in and risks related to the
Company’s ability to secure adequate pharmaceutical grade
quantities of Niagen IV in a timely manner; the Company’s ability
to obtain appropriate contracts and arrangements with U.S.
FDA-registered 503B outsourcing facilities required to distribute
Niagen IV to IV clinics; the Company’s ability to remain on the
U.S. FDA Bulk Drug Substances Nominated for Use in Compounding
Under Section 503B of the Federal Food, Drug, and Cosmetic Act
Category 1 list; the Company’s ability to maintain and enforce the
Company’s existing intellectual property and obtain new patents
related to Niagen IV; the Company’s ability to maintain sales,
marketing and distribution capabilities; changing consumer
perceptions of the Company’s products; the Company’s reliance on a
single or limited number of third-party suppliers; and the risks
and uncertainties associated with the Company’s business and
financial condition. More detailed information about ChromaDex and
the risk factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2023, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
About ChromaDex:
ChromaDex Corp. (NASDAQ:CDXC) is the global authority on
nicotinamide adenine dinucleotide (NAD+), with a focus on the
science of healthy aging. The ChromaDex team, comprised of
world-renowned scientists, works with independent investigators
from esteemed universities and research institutions around the
globe to uncover the full potential of NAD+. A vital coenzyme found
in every cell of the human body, NAD+ declines with age and
exposure to other everyday stressors. NAD+ depletion is a
contributor to age-related changes in health and vitality. Setting
the benchmark as the gold standard in scientific rigor and quality
in the dietary supplement space, ChromaDex is the innovator behind
its clinically proven flagship ingredient, Niagen® (patented
nicotinamide riboside, or NR). Clinically proven to increase NAD+
levels, Niagen is the most efficient and superior-quality NAD+
booster helping people transform the way they age.
Food-grade Niagen is manufactured by ChromaDex and is available
in the consumer dietary supplement Tru Niagen®, the number one
healthy-aging oral NAD+ supplement in the United States* (available
at www.truniagen.com). Pharmaceutical-grade Niagen will be
available through FDA-registered 503B outsourcing facilities and
will be administered at clinics pursuant to a valid prescription
(www.niagenplus.com).
ChromaDex’s robust patent portfolio protects NR and other NAD+
precursors. ChromaDex maintains a website at www.chromadex.com, to
which ChromaDex regularly publishes copies of its press releases,
news, and financial information.
*Based on the top-selling dietary supplement brands by revenue
per the largest U.S. e-commerce marketplace (as of
3/1/2023-2/29/2024).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240716150746/en/
ChromaDex Media Contact: Kendall Knysch, Senior Director
of Media Relations & Partnerships 310-388-6706 ext. 689
kendall.knysch@chromadex.com ChromaDex Investor Relations
Contact: Ben Shamsian Lytham Partners 646-829-9701
shamsian@lythampartners.com
Grafico Azioni ChromaDex (NASDAQ:CDXC)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni ChromaDex (NASDAQ:CDXC)
Storico
Da Gen 2024 a Gen 2025
